Company / Operating Income
Trevi Therapeutics, Inc. Operating Income History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$51.5M
FY2024
5-year range
-$51.5M / -$29.9M
FY2020-FY2024
Trend
-51.9%
vs FY2023
Sector context
#73 of 204
Health Care
What the data says
At -$52M, Trevi Therapeutics, Inc.'s operating income ranks #73 of 204 in the Health Care sector. Declined from -$30M to -$52M over the past 2 years.
Based on SEC 10-K filings.
-$52M in FY2024.
Declined from -$30M to -$52M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#73 of 204 in Health CareTop 36% of 204This company -$51.5M Sector average $107.7M
▼
-147.8% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 51.9% year-over-year.
- Ranks #73 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$51.5M | -51.9% |
| FY2023 | -$33.9M | -13.4% |
| FY2022 | -$29.9M | +7.9% |
| FY2021 | -$32.5M | +0.0% |
| FY2020 | -$32.5M | -21.9% |
| FY2019 | -$26.6M | -44.7% |
| FY2018 | -$18.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026